HCV treatment improvements reflected in graft, patient survival
In a retrospective analysis of transplant outcomes, the DAA era was associated with a 36% drop in mortality a year after transplant, according to George Cholankeril, MD, of the University of Tennessee Health Science Center in Memphis.
“Historically, about a third of grafts were lost in patients who were transplanted with HCV [hepatitis C virus],” and patients needed another transplant, Charlton noted. If the proportion of failure falls, it means that more organs are available for other patients, he said.
Another benefit in the DAA era is that more patients with HCV are being cured before they reach the stage transplant stage, so “there’s less need.”